1.1. Objective

1.2. Product Overview
  1.2.1. Market Segmentation
  1.2.2. Market & Segment Definitions

1.3. Research Methodology
  1.3.1. List of Primary & Secondary Sources
  1.3.2. Market Size Estimation
  1.3.2.1. Assumption for the Study
  1.3.2.2. Data Triangulation

Executive Summary: Global Respiratory Syncytial Virus Market

3.1. Industry Value Chain Analysis
  3.1.1. Research and Formulation
  3.1.2. Development and Packaging
  3.1.3. Sales and Distribution
  3.1.4. End Users

3.2. Industry Outlook
  3.2.1. Epidemiology and Patient Population
    3.2.1.1. Key Findings
    3.2.1.2. Epidem and Market Methodology
    3.2.1.3. 8MM Incident Patient Population of Respiratory Syncytial Virus
    3.2.2. Country Wise-Epidemiology of Respiratory Syncytial Virus
      3.2.2.1. United States Epidemiology
        3.2.2.1.1. Assumptions and Rationale
        3.2.2.1.2. Total Incident Cases of Respiratory Syncytial Virus in the United States
        3.2.2.1.3. Case-Specific Incidence of Respiratory Syncytial Virus in the United States
        3.2.2.1.4. Age-Specific Incidence of Respiratory Syncytial Virus in United States
        3.2.2.1.5. Incidence of Respiratory Syncytial Virus by Extremities (%) in the United States
    3.2.2.2. EU5 Epidemiology
        3.2.2.2.1. Germany
          3.2.2.2.1.1. Assumptions and Rationale
          3.2.2.2.1.2. Total Incident Cases of Respiratory Syncytial Virus in the Germany
          3.2.2.2.1.3. Case-Specific Incidence of Respiratory Syncytial Virus in the Germany
          3.2.2.2.1.4. Age-Specific Incidence of Respiratory Syncytial Virus in Germany
          3.2.2.2.1.5. Incidence of Respiratory Syncytial Virus by Extremities (%) in the Germany
        3.2.2.2.2. France
          3.2.2.2.2.1. Assumptions and Rationale
         3.2.2.2.2.2. Total Incident Cases of Respiratory Syncytial Virus in the France
          3.2.2.2.2.3. Case-Specific Incidence of Respiratory Syncytial Virus in the France
          3.2.2.2.2.4. Age-Specific Incidence of Respiratory Syncytial Virus in France
          3.2.2.2.2.5. Incidence of Respiratory Syncytial Virus by Extremities (%) in the France
        3.2.2.2.3. Italy
          3.2.2.2.3.1. Assumptions and Rationale
          3.2.2.2.3.2. Total Incident Cases of Respiratory Syncytial Virus in the Italy
          3.2.2.2.3.3. Case-Specific Incidence of Respiratory Syncytial Virus in the Italy
          3.2.2.2.3.4. Age-Specific Incidence of Respiratory Syncytial Virus in Italy
          3.2.2.2.3.5. Incidence of Respiratory Syncytial Virus by Extremities (%) in the Italy
        3.2.2.2.4. Spain
          3.2.2.2.4.1. Assumptions and Rationale
          3.2.2.2.4.2. Total Incident Cases of Respiratory Syncytial Virus in the Spain
          3.2.2.2.4.3. Case-Specific Incidence of Respiratory Syncytial Virus in the Spain
          3.2.2.2.4.4. Age-Specific Incidence of Respiratory Syncytial Virus in Spain
          3.2.2.2.4.5. Incidence of Respiratory Syncytial Virus by Extremities (%) in the Spain
        3.2.2.2.5. United Kingdom
          3.2.2.2.5.1. Assumptions and Rationale
          3.2.2.2.5.2. Total Incident Cases of Respiratory Syncytial Virus in the UK
          3.2.2.2.5.3. Case-Specific Incidence of Respiratory Syncytial Virus in the UK
          3.2.2.2.5.4. Age-Specific Incidence of Respiratory Syncytial Virus in UK
          3.2.2.2.5.5. Incidence of Respiratory Syncytial Virus by Extremities (%) in the UK
       3.2.2.3. Japan Epidemiology
          3.2.2.3.1. Assumptions and Rationale
          3.2.2.3.2. Total Incident Cases of Respiratory Syncytial Virus in the Japan
          3.2.2.3.3. Case-Specific Incidence of Respiratory Syncytial Virus in the Japan
          3.2.2.3.4. Age-Specific Incidence of Respiratory Syncytial Virus in Japan
          3.2.2.3.5. Incidence of Respiratory Syncytial Virus by Extremities (%) in the Japan
        3.2.2.4. China Epidemiology
          3.2.2.4.1. Assumptions and Rationale
          3.2.2.4.2. Total Incident Cases of Respiratory Syncytial Virus in the China
          3.2.2.4.3. Case-Specific Incidence of Respiratory Syncytial Virus in the China
          3.2.2.4.4. Age-Specific Incidence of Respiratory Syncytial Virus in China
          3.2.2.4.5. Incidence of Respiratory Syncytial Virus by Extremities (%) in the China
        3.2.2.5. India Epidemiology
          3.2.2.5.1. Assumptions and Rationale
          3.2.2.5.2. Total Incident Cases of Respiratory Syncytial Virus in the India
          3.2.2.5.3. Case-Specific Incidence of Respiratory Syncytial Virus in the India
          3.2.2.5.4. Age-Specific Incidence of Respiratory Syncytial Virus in India
          3.2.2.5.5. Incidence of Respiratory Syncytial Virus by Extremities (%) in the India
  3.2.3. Treatment and Management of Respiratory Syncytial Virus
    3.2.3.1. Scope of Treatment
    3.2.3.2. Treatment Guidelines
    3.2.3.3. American Academy of Pediatrics guidelines for Respiratory Syncytial Virus
  3.2.4. Unmet Needs
  3.2.5. Marketed Drugs
    3.2.5.1. Synagis (Palivizumab): MedImmune/Abbott Laboratories Inc.
      3.2.5.1.1. Product Description
      3.2.5.1.2. Regulatory Milestones
      3.2.5.1.3. Clinical Development
      3.2.5.1.4. Ongoing Current Pipeline Activity
      3.2.5.1.5. Safety and efficacy
      3.2.5.1.6. Product Profile
    3.2.5.2. Virazole (Ribavirin): ICN Pharmaceuticals
      3.2.5.2.1. Product Description
      3.2.5.2.2. Regulatory Milestones
      3.2.5.2.3. Clinical Development
      3.2.5.2.4. Ongoing Current Pipeline Activity
      3.2.5.2.5. Safety and efficacy
      3.2.5.2.6. Product Profile
  3.2.6. Emerging Drugs
    3.2.6.1. EDP 938: Enanta Pharmaceuticals
      3.2.6.1.1. Product Description
      3.2.6.1.2. Other Development Activities
      3.2.6.1.3. Clinical Development
      3.2.6.1.4. Clinical Trials Information
      3.2.6.1.5. Safety and Efficacy
      3.2.6.1.6. Product Profile
    3.2.6.2. Nirsevimab: AstraZeneca
      3.2.6.2.1. Product Description
      3.2.6.2.2. Other Development Activities
      3.2.6.2.3. Clinical Development
      3.2.6.2.4. Clinical Trials Information
      3.2.6.2.5. Safety and Efficacy
      3.2.6.2.6. Product Profile
    3.2.6.3. MEDI8897: MedImmune LLC
      3.2.6.3.1. Product Description
      3.2.6.3.2. Other Development Activities
      3.2.6.3.3. Clinical Development
      3.2.6.3.4. Clinical Trials Information
      3.2.6.3.5. Safety and Efficacy
      3.2.6.3.6. Product Profile
    3.2.6.4. JNJ-53718678: Janssen Sciences Ireland UC
      3.2.6.4.1. Product Description
      3.2.6.4.2. Other Development Activities
      3.2.6.4.3. Clinical Development
      3.2.6.4.4. Clinical Trials Information
      3.2.6.4.5. Safety and Efficacy
      3.2.6.4.6. Product Profile
    3.2.7. Target population and RSV vaccine
      3.2.7.1. Maternal
      3.2.7.2. Infants
      3.2.7.3. Children
      3.2.7.4. Elderly
    3.2.8. RSV Vaccines in pipeline

3.3. PESTLE Analysis

3.4. Porter's Five Forces Analysis
  3.4.1. Bargaining Power of Suppliers
  3.4.2. Bargaining Power of Buyers
  3.4.3. Threat of Substitutes
  3.4.4. Threat of New Entrants
  3.4.5. Degree of Competition

3.5. Market Dynamics and Trends
  3.5.1. Key Trends
  3.5.2. Growth Drivers
  3.5.3. Restraints/ Challenges
  3.6. Market Growth and Outlook
  3.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2019-2032
  3.6.2. Pricing Analysis

3.7. Covid-19 Impact Assessment on Market Growth Trend
  3.7.1. Growth Trend Shift Analysis
  3.7.2. Industry Best Practices

3.8. Regulatory Landscape

4.1. Market Concentration Rate

4.2. Company Market Share Analysis (Value %), 2023

4.3. Competitor Mapping

5.1. Key Insights

5.2. Market Size and Forecast, 2019 – 2032 (US$ Mn)
  5.2.1. Ribavirin
  5.2.2. Synagis
  5.2.3. Virazole
  5.2.4. Palivizumab
  5.2.5. Riba Tab
  5.2.6. Others

6.1. Key Insights

6.2. Market Size and Forecast, 2019 – 2032 (US$ Mn)
  6.2.1. Oral
  6.2.2. Injectable
  6.2.3. Inhaler
  6.2.4. Others

7.1. Key Insights

7.2. Market Size and Forecast, 2019 – 2032 (US$ Mn)
  7.2.1. Immune prophylaxis
  7.2.2. Supportive care
  7.2.3. Antiviral Medications

8.1. Key Insights

8.2. Market Size and Forecast, 2019 – 2032 (US$ Mn)
  8.2.1. Hospital pharmacies
  8.2.2. Drug Stores
  8.2.3. Retail pharmacies
  8.2.4. Clinics

9.1. Key Insights

9.2. Market Size and Forecast, 2019 – 2032 (US$ Mn)
  9.2.1. North America 
    9.2.1.1. The U.S.
    9.2.1.2. Canada
    9.2.1.3. Mexico
  9.2.2. Europe  
    9.2.2.1. The UK
    9.2.2.2. Germany
    9.2.2.3. France
    9.2.2.4. Italy
    9.2.2.5. Spain
    9.2.2.6. Poland 
    9.2.2.7. Russia
    9.2.2.8. Rest of Europe
  9.2.3. Asia Pacific 
    9.2.3.1. China
    9.2.3.2. India
    9.2.3.3. Japan
    9.2.3.4. Australia & New Zealand
    9.2.3.5. ASEAN
    9.2.3.6. Rest of Asia Pacific
  9.2.4. Middle East & Africa
    9.2.4.1. UAE
    9.2.4.2. Saudi Arabia
    9.2.4.3. South Africa
    9.2.4.4. Rest of MEA
    9.2.5. South America
      9.2.5.1. Argentina
      9.2.5.2. Brazil
      9.2.5.3. Rest of South America

10.1. Key Insights

10.2. Market Size and Forecast, 2019 – 2032 (US$ Mn)
  10.2.1. By Drug type
  10.2.2. By Dosage form
  10.2.3. By Treatment type
  10.2.4. By Distribution channel
  10.2.5. By Country

11.1. Key Insights

11.2. Market Size and Forecast, 2019 – 2032 (US$ Mn)
  11.2.1. By Drug type
  11.2.2. By Dosage form
  11.2.3. By Treatment type
  11.2.4. By Distribution channel
  11.2.5. By Country

12.1. Key Insights

12.2. Market Size and Forecast, 2019 – 2032 (US$ Mn)
  12.2.1. By Drug type
  12.2.2. By Dosage form
  12.2.3. By Treatment type
  12.2.4. By Distribution channel
  12.2.5. By Country

13.1. Key Insights

13.2. Market Size and Forecast, 2019 – 2032 (US$ Mn)
  13.2.1. By Drug type
  13.2.2. By Dosage form
  13.2.3. By Treatment type
  13.2.4. By Distribution channel
  13.2.5. By Country

14.1. Key Insights

14.2. Market Size and Forecast, 2019 – 2032 (US$ Mn)
  14.2.1. By Drug type
  14.2.2. By Dosage form
  14.2.3. By Treatment type
  14.2.4. By Distribution channel
  14.2.5. By Country

15.1. AbbVie, Inc.
15.2. AstraZeneca PLC
15.3. Atea Pharmaceuticals
15.4. Bausch Health Companies Inc.
15.5. Celltrion Inc.
15.6. Enanta Pharmaceuticals, Inc
15.7. F. Hoffmann-La Roche AG
15.8. Gilead Sciences, Inc.
15.9. GlaxoSmithKline PLC
15.10. Johnson & Johnson’s
15.11. mAbxience
15.12. Medivir AB
15.13. Merck Co., Inc.
15.14. Pfizer Inc.
15.15. ReViral Ltd.
15.16. Sanofi
15.17. Teva Pharmaceutical Industries Ltd.
15.18. Other players